<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005000</url>
  </required_header>
  <id_info>
    <org_study_id>21-00996</org_study_id>
    <nct_id>NCT05005000</nct_id>
  </id_info>
  <brief_title>Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis</brief_title>
  <official_title>Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      32 patients with Eaton-Glickel stage 2-3 CMC arthritis will be randomized to receive&#xD;
      intraarticular MFAT or intraarticular corticosteroid injection. Patients with inflammatory&#xD;
      arthritis or prior thumb base trauma or surgery will be excluded. Autologous adipose tissue&#xD;
      will be harvested from the outer thigh or lower abdomen using local anesthesia. Tissue will&#xD;
      be processed to remove oil and debris in-office using an FDA-approved commercially available&#xD;
      device. The processed adipose will be immediately injected into the thumb CMC joint under&#xD;
      fluoroscopic guidance. Visual analogue score (VAS), grip/pinch strength, Kapandji range of&#xD;
      motion score, thumb disability examination, and QuickDASH score will be assessed&#xD;
      pre-procedure and at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Score on Pain Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Pain severity scores will be assessed by use of a visual analog scale (VAS; total range = 0-10; 0 = no pain, 10 = worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Thumb Disability Exam (TDX)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>TDX consists of 20 questions and assess the function of the participant's thumbs over the past week. Each question is scored from 1 (not difficult) to 5 (unable).&#xD;
TDX is scored on a scale of 1 to 100, with a higher score indicating a greater degree of disability in the thumb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Shortened Disabilities of the Arm, Shoulder, and Hand (QuickDASH) Score</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>QuickDASH consists of 11 questions -- the participants are asked to rate their ability to do activities in the last week on a scale of 1 (no difficulty) to 5 (unable). The disability/symptom score is calculated by ((sum of n responses/n)-1)x25, where n is equal to the number of completed responses. The total score ranges from 0 to 250; higher scores indicate greater degree of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kapandji Range of Motion Score</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>A Kapandji score is used to assess the movement of opposition (being able to touch one's thumb to areas of one's hand). It is vital in hand function and grip. The total score ranges from 1 to 10; a higher score indicates the thumb being able to touch a further area on the hand.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>MFAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Micro-Fragmented Adipose Tissue (MFAT)</intervention_name>
    <description>1ml of autologous micro-fragmented adipose tissue will be used.</description>
    <arm_group_label>MFAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide 10mg/mL</intervention_name>
    <description>The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.</description>
    <arm_group_label>Steroid (Control)</arm_group_label>
    <other_name>Kenalog-10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years old or older; male and female patients&#xD;
&#xD;
          2. Eaton-Glickel stage 2-3 thumb CMC arthritis&#xD;
&#xD;
          3. Failed conservative treatment (i.e. hand therapy, pain medications, splinting)&#xD;
&#xD;
          4. Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy/breastfeeding&#xD;
&#xD;
          2. Inflammatory or posttraumatic arthritis&#xD;
&#xD;
          3. Prior thumb base trauma or surgery&#xD;
&#xD;
          4. Evidence of skin infection or soft tissue loss at the thumb CMC joint or adipose&#xD;
             harvest site&#xD;
&#xD;
          5. Active local or systemic malignancy&#xD;
&#xD;
          6. Known allergy to any study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Hacquebord, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Venus Vakhshori, MD</last_name>
    <phone>818-605-3779</phone>
    <email>Venus.vakhshori@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madeline Rocks, MD</last_name>
    <email>Madeline.rocks@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Madeline Rocks</last_name>
      <email>Madeline.rocks@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Jacques Hacquebord, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Venus Vakhshori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Glickel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data upon reasonable request. Requests should be directed to Jacques.Hacquebord@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

